Enantiomerically pure .beta.-d-dioxolane nucleosides
AssigneesEmory University, University of Georgia Research Foundation, Inc.
InventorsChung K. Chu, Raymond F. Schinazi
Life of this patent
Estimating the term…
Abstract
A method and composition for the treatment of humans infected with HIV that includes the administration of an HIV treatment amount of an enantiomerically pure .beta.-D-dioxolanyl purine nucleoside of the formula: ##STR1## wherein R is OH, Cl, NH.sub.2, or H, or a pharmaceutically acceptable salt or derivative of the compound, optionally in a pharmaceutically acceptable carrier or diluent.
Claims13
An enantiomerically pure .beta.-D-dioxolanyl nucleoside of the structure:
- ##STR4## wherein R is OH, and X is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate, or its pharmaceutically acceptable salt, and wherein the compound is at least 97% free of the corresponding .beta.-L-enantiomer.
An enantiomerically pure .beta.-D-dioxolanyl nucleoside of the structure:
- ##STR5## wherein R is NH.sub.2, and X is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate, or its pharmaceutically acceptable salt, and wherein the compound is at least 97% free of the corresponding .beta.-L-enantiomer.
An enantiomerically pure .beta.-D-dioxolanyl nucleoside of the structure:
- ##STR6## wherein R is H or Cl, and X is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate, or a pharmaceutically acceptable salt thereof, and wherein the compound is at least 97% free of the corresponding .beta.-L-enantiomer.
(-)-(2R,4R)-9-(-2-hydroxymethyl)-1,3-dioxolan-4-yl!guanine, which is at least 97% free of the corresponding .beta.-L-enantiomer.
(-)-(2R,4R)-2-amino-9-(2-hydroxymethyl)-1,3-dioxolan-4-yl!adenine, which is at least 97% free of the corresponding .beta.-L-enantiomer.
(-)-(2R,4R)-2-amino-9-(-2-hydroxymethyl)-1,3-dioxolan-4-yl!purine, which is at least 97% free of the corresponding .beta.-L-enantiomer.
(-)-(2R,4R)-2-amino-6-chloro-9-(2-hydroxymethyl)- 1,3-dioxolan-4-yl!purine, which is at least 97% free of the corresponding .beta.-L-enantiomer.
Dependencies are inferred from the claim text.